First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

NCT03507452 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma
Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma
Advanced Recurrent Serous Ovarian Cancer
Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

Interventions

DRUG: BAY2287411
DRUG: BAY2287411

Sponsor

Bayer